Marc Abrams

Dicerna Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index2.8kcitations83works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(19), MicroRNA in disease regulation(14), RNA modifications and cancer(12), RNA Research and Splicing(11), Advanced biosensing and bioanalysis techniques(9)

Publications83 total

Abstract 12705: Identification and Characterization of Solbinsiran, a GalNAc Conjugated siRNA Targeting Angiopoietin-Like 3
Circulation·2023· 4 cited
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Cholesterol-Conjugated siRNA Silencing <i>Tnf</i> for the Treatment of Liver Macrophage-Mediated Acute Inflammation in Nonalcoholic Fatty Liver Disease
Nucleic Acid Therapeutics·2022· 6 cited
Abstract 1502: KRAS RNAi therapy in preclinical models of pancreatic cancer sensitizes tumors to checkpoint blockade by affecting the tumor microenvironment
Cancer Research·2019
Loss of hepatocyte β-catenin protects mice from experimental porphyria-associated liver injury
Journal of Hepatology·2018· 35 cited
Hepatocyte‐Specific β‐Catenin Deletion During Severe Liver Injury Provokes Cholangiocytes to Differentiate Into Hepatocytes
Hepatology·2018· 140 citedOpen Access
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
Molecular Therapy·2018· 120 citedOpen Access
Abstract B03: RNAi-mediated β-catenin inhibition sensitizes noninflamed tumors to immune checkpoint blockade
Cancer Immunology Research·2018· 1 cited
Direct Inhibition of β-catenin: A new strategy for colorectal cancer
Oncoscience·2018Open Access
page 1 of 5Next →

Frequent Co-authors

Carolyn A. Buser(13), George D. Hartman(13), Robert B. Lobell(12), Joseph P. Davide(11), Weimin Wang(11), Martin L. Koser(10), Laura Sepp‐Lorenzino(10), Eileen S. Walsh(10), Samuel Graham(9), Shanthi Ganesh(9), Bob D. Brown(9), Nancy E. Kohl(8), Kelly Hamilton(8), Theresa M. Williams(7), R. M. Garbaccio(7), Hans E. Huber(7), Kevin P. Craig(7), R. Robinson(7), Michelle Ellis-Hutchings(6), Weikang Tao(6)